Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Business & Industry
- U.S. Food and Drug Administration expands approval of Yervoy® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma
- Merck and Pfizer collaborate with Corning
- Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation
- Merck Biopharma Innovation Cup 2017
- Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
Research & Development
- Antidepressant use in pregnant women linked to small increase in autism
- How physical exercise prevents dementia
- 27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next 5 years
- New way found to boost immunity in fight cancer and infections
- One minute of running per day associated with better bone health in women
- A new ligand extends the half-life of peptide drugs from minutes to days
- Cancer cells force normal cells to mimic viruses to help tumors spread, resist treatment
Conferences & Events
- IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies
- The future has arrived #CUBETechFair
- eyeforpharma Philadelphia 2017: Be the trusted healthcare partner #efpPhilly
- DIA EuroMeeting explores the road ahead for drug development in the EU and UK
- CUBE Tech Fair welcomes spectacular speakers
- Post-Authorisation Studies
- CUBE TECH FAIR 2017: Experience the 4th Industrial Revolution
Regulatory Affairs
- FDA approves Vosevi for Hepatitis C
- FDA tackles drug competition to improve patient access
- Statement from FDA Commissioner Scott Gottlieb, M.D., on the importance of the Drug Quality and Security Act and overseeing the safety of compounded drugs
- FDA approves first generic Strattera for the treatment of ADHD
- Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions
- FDA approves first cancer treatment for any solid tumor with a specific genetic feature
- FDA approves drug to treat ALS